Educational content, not medical advice. This article compares the prescribing information for two brand names of liraglutide. It does not recommend either product for any reader, and questions about which medicine fits a given person belong with that person's prescriber.

Ask a search box which of these two pens is stronger and the honest answer from the labels is that the question is built on a wrong assumption. Victoza and Saxenda hold the same liquid at the same strength. What differs is the dial on the pen, the job each label approves it for, and one printed checkpoint that exists on one label and not the other. Strength never enters the picture, because the molecule never changes.

People arrive at this comparison from both directions, usually after a formulary change or a new prescription, and the short answer is a plain one: same liquid, different dial, different approved purpose. The daily-injection rhythm itself, and how to keep a reliable record across it, has a full guide in Daily GLP-1 Injections: Tracking Saxenda and Victoza.

The same liquid at the same strength

The supply details make the point precisely. Victoza is supplied as 18 mg per 3 mL, which is 6 mg/mL, in a prefilled single-patient-use pen that delivers 0.6 mg, 1.2 mg or 1.8 mg. Saxenda is supplied as 6 mg/mL in a 3 mL single-patient-use prefilled pen that delivers 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg. Identical concentration, identical volume, identical daily injection underneath. The deliverable doses are the entire difference in hardware, and the numbers on the dials are why one pen runs out of rungs before the other.

That construction also explains why the two labels warn against stacking. Victoza's Limitations of Use says coadministration with other liraglutide-containing products is not recommended. Saxenda's says coadministration with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended. Same medicine twice over is not a strategy either label supports, and Saxenda extends the caution to the whole class.

Two approved jobs, two age groups

Victoza's indications sit in diabetes care. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. The youngest patients this label reaches are 10.

Saxenda's indications sit on the weight side. It is indicated, in combination with a reduced calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity, and in adults with overweight in the presence of at least one weight-related comorbid condition. Saxenda's label adds that its safety and effectiveness in pediatric patients with type 2 diabetes have not been established, which keeps the two jobs cleanly apart even where the age ranges overlap.

Two ladders of different shapes

The dose schedules differ in geometry, not just height. Victoza starts at 0.6 mg once daily for one week, a dose the label says is intended to reduce gastrointestinal adverse reactions during titration and is not effective for glycemic control in adults, then goes to 1.2 mg, then to a maximum of 1.8 mg if additional glycemic control is required after at least a week at 1.2 mg. It is a short ladder with a conditional top rung. Why starting doses exist at all, across every product in the class, is the subject of GLP-1 Titration Schedules Explained, Medication by Medication.

Saxenda runs a fixed weekly schedule: 0.6 mg in week 1, 1.2 mg in week 2, 1.8 mg in week 3, 2.4 mg in week 4, and 3 mg from week 5 onward. For adults the recommended dosage is 3 mg daily, and the label calls the lower dosages titration only. So the first ladder climbs until glycemic control is adequate and stops, while the second climbs all the way to its ceiling on a calendar. Neither shape is gentler or more aggressive than the other; they are built for different endpoints, and where any individual lands is a prescriber's judgment on tolerance and response.

GLP 1 Tracker AppTrack a daily liraglutide dose with either ladder as a preset, plus injection site notes and a weight trend, all on your phone. Get the app

The checkpoint on one label only

Saxenda's label writes down two rules that Victoza's does not carry, both addressed to clinicians. The first: discontinue Saxenda if the patient cannot tolerate the 3 mg dosage. The second: evaluate the change in body weight 16 weeks after starting, and discontinue if the patient has not lost at least 4% of baseline body weight, since it is unlikely that continued treatment will produce and sustain clinically meaningful weight loss. Among the current weight-management labels that scheduled look is Saxenda's alone. Wegovy, Zepbound and Foundayo print no equivalent checkpoint.

The pediatric section softens the climb rather than the checkpoint. For pediatric patients, Saxenda's escalation may take up to 8 weeks, the dose may be lowered to the previous level if a step is not tolerated, and patients who do not tolerate 3 mg daily may have the dose reduced to 2.4 mg daily. Every one of these sentences is an instruction to a prescriber. What a reader takes from them is that the schedule in the pamphlet is a default with written exceptions, applied case by case, never a script to adjust by hand.

What the two labels share

The missed-dose rule reads the same on both: resume the once-daily regimen with the next scheduled dose, never an extra dose and never an increased dose to make up for the missed one, and if more than 3 days have elapsed since the last dose, reinitiate at 0.6 mg daily and follow the escalation schedule again. Administration is the same on both: subcutaneous, once daily, at any time of day, without regard to meals, in the abdomen, thigh or upper arm. Storage is the same on both: refrigerated at 36 to 46 F before first use, never frozen, and after first use the pen may be kept for 30 days at a controlled room temperature of 59 to 86 F or in the refrigerator.

Generics now exist on both sides, and they are not uniform, which is the last thing worth knowing before assuming the paper in the box matches a brand. The weight-management generic carries Saxenda's indication wording. Among the diabetes-side generic liraglutide labels, some carry both the glycemic control indication and the cardiovascular risk reduction indication, and some list only glycemic control. That spread is a reason to read the label that comes in the box rather than the name on it, a habit Generic Liraglutide: The First Generic GLP-1 goes into at length. Whether the question is a substitution at the counter or a first prescription, the pair of pens resolves the same way: one liquid, two dials, two jobs, and a prescriber holding the pen.

Frequently asked questions

Is Saxenda stronger than Victoza?

No. Both pens hold liraglutide at the same concentration, 6 mg/mL, and the difference is the dial: a Saxenda pen can deliver 0.6, 1.2, 1.8, 2.4 or 3 mg, while a Victoza pen delivers 0.6, 1.2 or 1.8 mg. A higher deliverable dose is not a stronger medicine, and the two labels approve them for different purposes in different age groups.

Can Victoza and Saxenda be used together?

No. Both labels address the question directly. Victoza says coadministration with other liraglutide-containing products is not recommended, and Saxenda goes further, saying coadministration with other liraglutide-containing products or with any other GLP-1 receptor agonist is not recommended. Using both would mean taking the same molecule twice in a day, which neither label contemplates.

Do Victoza and Saxenda have the same dose schedule?

They share the first step and then diverge. Both begin at 0.6 mg once daily. Victoza then moves to 1.2 mg, and up to a maximum of 1.8 mg if additional glycemic control is required after at least a week. Saxenda climbs on a fixed weekly schedule through 1.2, 1.8 and 2.4 mg to 3 mg from week 5 onward, which is the recommended adult dosage; the label calls the lower dosages titration only.

What happens if I miss a daily liraglutide dose?

The rule reads the same on both labels. Resume the once-daily regimen with the next scheduled dose, never an extra dose and never an increased dose to make up for the missed one. If more than 3 days have elapsed since the last dose, the label says to reinitiate at 0.6 mg daily and follow the escalation schedule again. A prescriber guides anything beyond that.

Is there a generic version of either pen?

Generic liraglutide exists on both the diabetes side and the weight side, and the labels are not uniform. The weight-management generic carries Saxenda's indication wording. Among diabetes-side generics, some carry both the glycemic control indication and the cardiovascular risk reduction indication, and some list only glycemic control. Reading the label in the box beats assuming a generic matches the brand it replaces.